<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781287</url>
  </required_header>
  <id_info>
    <org_study_id>34908-D</org_study_id>
    <nct_id>NCT00781287</nct_id>
  </id_info>
  <brief_title>Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1</brief_title>
  <acronym>UW PIC 330</acronym>
  <official_title>Impact of Raltegravir (Isentress/MK-0518) - Containing Regimens on HIV-1 Infected CD4+ T-Cells During Acute and Early HIV-1 Infection: A Randomized, Controlled Study Comparing Standard Antiretroviral Therapy to Standard Therapy Plus Raltegravir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, two-year, randomized, controlled, single-center,
      open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to
      3-drug HAART plus raltegravir for persons with acute and early HIV-1 infection. The study
      will test the hypothesis that use of the integrase inhibitor raltegravir (400 mg BID orally)
      to inhibit the integration step of the HIV-1 life cycle in conjunction with HAART in subjects
      with recently acquired HIV-1 infection will decrease the number of HIV-1 infected CD4+
      T-cells to a greater extent than a 3-drug HAART regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at the UW Primary Infection Clinic and the UW AIDS Clinical
      Trials Unit. Secondary objectives will characterize safety, tolerability, plasma HIV-1 RNA
      and CD4+ T-cell values. The 3-drug HAART will be chosen and provided by the subject.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment too slow.
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of HIV-1 infected CD4+ T-cells measured by a quantitative HIV-1 DNA PCR assay</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cells</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 and 4 signs and symptoms or laboratory toxicities at least one grade higher than baseline</measure>
    <time_frame>From study drug start to 8 weeks after drug discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability (Discontinuation of raltegravir)</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Raltegravir + 3-drug anti-HIV therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3-drug anti-HIV therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3-drug anti-HIV therapy</intervention_name>
    <description>3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)</description>
    <arm_group_label>Raltegravir + 3-drug anti-HIV therapy</arm_group_label>
    <arm_group_label>3-drug anti-HIV therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400 mg BID PO</description>
    <arm_group_label>Raltegravir + 3-drug anti-HIV therapy</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute or Early HIV-1 infection

          -  HIV-1 RNA &gt; or equal to 500 copies/mL

          -  Acceptable safety lab results (specified in protocol)

          -  Negative pregnancy test for females

          -  Willingness to use contraception (for females of reproductive potential

        Exclusion Criteria:

          -  Prior receipt of investigational HIV-1 vaccine

          -  Use of immunomodulators other than systemic steroids within 30 days before entry

          -  Serious medical or psychiatric illness that would interfere with study participation

          -  Active drug or alcohol use that would interfere with study participation

          -  Allergy/hypersensitivity to raltegravir

          -  Pre- or Post-exposure prophylaxis for the exposure that led to HIV-1 acquisition

          -  Pregnancy or breastfeeding

          -  History of malignancy (other than localized squamous cell or basal cell cancer of the
             skin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann C. Collier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Primary Infection Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/hpic/</url>
    <description>University of Washington Primary Infection Clinic web site</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ann Collier</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>human immunodeficiency virus</keyword>
  <keyword>raltegravir</keyword>
  <keyword>primary HIV infection</keyword>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 15, 2017</submitted>
    <returned>June 6, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

